1. Home
  2. TALO vs ADMA Comparison

TALO vs ADMA Comparison

Compare TALO & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TALO

Talos Energy Inc.

HOLD

Current Price

$13.97

Market Cap

2.5B

Sector

Energy

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$8.64

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALO
ADMA
Founded
2011
2004
Country
United States
United States
Employees
N/A
647
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
1.9B
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
TALO
ADMA
Price
$13.97
$8.64
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$18.00
$25.67
AVG Volume (30 Days)
1.7M
3.4M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.19
Revenue
$1,780,070,000.00
$42,219,783.00
Revenue This Year
$4.18
$27.46
Revenue Next Year
N/A
$22.11
P/E Ratio
N/A
$43.74
Revenue Growth
N/A
43.85
52 Week Low
$7.67
$7.21
52 Week High
$17.05
$20.46

Technical Indicators

Market Signals
Indicator
TALO
ADMA
Relative Strength Index (RSI) 41.28 52.43
Support Level $10.49 $7.38
Resistance Level $16.01 $8.90
Average True Range (ATR) 0.56 0.33
MACD -0.12 0.14
Stochastic Oscillator 22.96 83.39

Price Performance

Historical Comparison
TALO
ADMA

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: